CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels
Portfolio Pulse from Benzinga Newsdesk
The CDC reports no cases of Clade I Mpox in the U.S. as of September 6, while Clade II Mpox continues to circulate at low levels.
September 06, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Emergent BioSolutions (EBS) may be impacted by the CDC's report on Mpox, as the company is involved in public health threat responses.
EBS is involved in public health responses, and the CDC's report on Mpox could influence demand for related products. However, the low level of Clade II circulation suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
GeoVax Labs (GOVX) may be affected by the CDC's Mpox update, as the company is involved in vaccine development.
GOVX is involved in vaccine development, and the CDC's report on Mpox could affect interest in their products. The low circulation level of Clade II suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Inovio Pharmaceuticals (INO) could be impacted by the CDC's Mpox report, given their focus on infectious disease solutions.
INO focuses on infectious disease solutions, and the CDC's update on Mpox could influence their market. The low level of Clade II circulation suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Moderna (MRNA) might be influenced by the CDC's Mpox update, as the company is involved in vaccine development.
MRNA is involved in vaccine development, and the CDC's report on Mpox could affect interest in their products. The low circulation level of Clade II suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50